This antibody is purified through a protein A column, followed by peptide affinity purification.
Immunogen
This COP1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 37-65 amino acids from the N-terminal region of human COP1.
RFWD2
Reaktivität: Human
WB, ELISA
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
For FACS starting dilution is: 1:10~50
For WB starting dilution is: 1:1000
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
0.35 mg/mL
Buffer
Supplied in PBS with 0.09 % (W/V) sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C,-20 °C
Informationen zur Lagerung
Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Target
RFWD2
(Ring Finger and WD Repeat Domain 2, E3 Ubiquitin Protein Ligase (RFWD2))
COP1 antikoerper, RNF200 antikoerper, AI316802 antikoerper, C80879 antikoerper, Cop1 antikoerper, RGD1304773 antikoerper, RFWD2 antikoerper, cop1 antikoerper, rnf200 antikoerper, zgc:163067 antikoerper, ring finger and WD repeat domain 2 antikoerper, ring finger and WD repeat domain 2, E3 ubiquitin protein ligase antikoerper, ring finger and WD repeat domain 2, E3 ubiquitin protein ligase L homeolog antikoerper, RFWD2 antikoerper, Rfwd2 antikoerper, rfwd2 antikoerper, rfwd2.L antikoerper
Hintergrund
Caspase inhibitor. Acts as a regulator of procaspase-1/CASP1 activation implicated in the regulation of the proteolytic maturation of pro-interleukin-1 beta (IL1B) and its release during inflammation. Inhibits the release of IL1B in response to LPS in monocytes. Also induces NF-kappa-B activation during the pro-inflammatory cytokine response. Also able to inhibit CASP1-mediated neuronal cell death, TNF-alpha, hypoxia-, UV-, and staurosporine-mediated cell death but not ER stress-mediated cell death. Acts by preventing activation of caspases CASP1 and CASP4, possibly by preventing the interaction between CASP1 and RIPK2.